Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2016-03-09 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Placing and Open Offer Close
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (5830R) and the date (09 March 2016), indicating it is a regulatory announcement from the London Stock Exchange's RNS service. The content announces the successful completion of a 'Firm Placing' which raised £3.4 million through the issuance of new ordinary shares. This action directly relates to capital raising and financing activities, fitting the 'Capital/Financing Update' (CAP) definition. Although it mentions Director Dealings, the primary purpose is the fundraising announcement. Since it is a specific announcement of a financing event, CAP is more appropriate than the general fallback RNS or the specific DIRS code.
2016-03-09 English
Proposed Placing and Open Offer
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement dated March 9, 2016, detailing a 'Proposed Placing and Open Offer' to raise approximately £6.8 million through the issue of new ordinary shares. This action directly relates to fundraising, capital structure changes, and the issuance of new shares. This fits the definition of 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA). Since the core activity described is the proposal and execution of a capital raise via placing and open offer, 'Capital/Financing Update' (CAP) is highly appropriate, as it covers fundraising activities. 'SHA' is also relevant as it involves a new share issue, but 'CAP' often encompasses the entire fundraising event, including the rationale and structure (placing/offer). Given the explicit focus on raising capital (£6.8 million) and the mechanics of the placing/open offer, CAP is the best fit. The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2016-03-09 English
Amendment to Options
Remuneration Information Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an announcement from 'Scancell Holdings Plc' dated '27 January 2016'. The content discusses an 'Amendment to Options' granted to executives, specifically extending the exercise period. This type of announcement, which details changes in executive compensation/incentives (options), aligns closely with Remuneration Information (DEF 14A) or Director's Dealing (DIRS) if it were a trade. However, the core subject is the modification of incentive awards for management, which falls under governance/remuneration disclosures. Since it is a formal announcement distributed via RNS, and it concerns executive compensation terms, it is best classified as related to remuneration, though it is not a full DEF 14A. Given the options provided, the closest fit for executive incentive changes is often grouped with remuneration disclosures. However, looking strictly at the definitions, this is a specific corporate action announcement distributed via RNS. Since it is a short, specific announcement distributed via RNS about executive incentives (options), and not a full report, it fits the general 'Regulatory Filings' (RNS) category as a fallback, or potentially relates to management/remuneration. Since it is an announcement about executive options/incentives, and not a trade (DIRS) or a full remuneration report (DEF 14A), the most accurate general classification for a non-standard regulatory update distributed via RNS is RNS itself, or potentially MANG if it were a change in role. Given the specific nature of option amendment, and the presence of the RNS header, RNS is the safest classification for a non-standard filing, although it touches upon executive compensation structure.
2016-01-27 English
Half Yearly Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 31 October 2015' and contains substantive financial data, including a Profit and Loss Account, Balance Sheet, and detailed management commentary on business operations and clinical trials. It is a comprehensive interim report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). H1 2015
2016-01-27 English
SCIB1 Early Immune Effect Observed by ImmunTraCkeR
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 3689L' and is dated January 11, 2016. It details scientific and clinical trial updates regarding Scancell's SCIB1 cancer vaccine and its companion diagnostic, ImmunTraCkeR®. The content is a press release announcing scientific findings and future trial plans, not a formal regulatory report like a 10-K or an earnings release (ER). Since it is a general announcement disseminated through the RNS system that doesn't fit into the more specific categories (like DIV, DIRS, or CT), the most appropriate classification is the general regulatory announcement category, RNS.
2016-01-11 English
Directorate Change
Board/Management Information Classification · 99% confidence The document is identified by the presence of an 'RNS Number' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly announces a 'Directorate Change'—the appointment of a new Non-Executive Chairman and the resignation of the outgoing Chairman. This type of announcement regarding changes in senior management or the board of directors directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2016-01-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.